NDAINTRAVENOUSSOLUTION
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
7/8 — Comprehensive
CALCIUM GLUCONATE (calcium gluconate) by Fresenius Kabi is level. Approved for colorectal cancer, neurotoxicity, osteoporosis and 5 more indications. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Calcium gluconate is an intravenous solution containing ionized calcium that dissociates into normal body fluid constituents. It is indicated for management of chemotherapy-induced toxicity, neurotoxicity, neuropathy, and supportive care in oncology (colorectal and prostate cancer), trauma, and hemorrhage. The mechanism replenishes serum calcium levels and restores normal cellular function disrupted by cancer treatment or acute injury.
$59KPart D
Peak11.2 years to LOEMinimal commercial scale with negligible Part D spending and 564 annual claims indicates a niche supportive care product with limited team growth potential.
Mechanism of Action
level. Calcium gluconate dissociates into ionized calcium in plasma. Ionized calcium and gluconate are normal constituents of body fluids.
Worked on CALCIUM GLUCONATE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.